Conclusions
- BRAF-and MYB-altered gliomas displayed high immune activation relative to other tumors.
- IDH WT tumors have an immune suppressive microenvironment with relatively high immune checkpoint expression.
- Based on predictive markers, BRAF-and MYB-driven gliomas show signatures suggesting the possibility of a greater response to immunotherapies than IDH WT/mutant gliomas or H3-3A mutant gliomas.